Should you buy Kempharm (kmph) stock based on options?
Apr 11, 2022 · KMPH KemPharm — Stock Price and Discussion | Stocktwits. KemPharm NASDAQ Updated Apr 8, 2022 11:59 PM. KMPH 4.77 0.30 (5.92%) Post-Market 0.03 (0.63%) 23,212. Key Data. 52wk Low 4.89.
How much did kmph raise in its IPO?
KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It …
How much of KemPharm's stock is owned by insiders?
Apr 13, 2022 · Analyst Forecast. According to 8 analysts, the average rating for KMPH stock is "Buy." The 12-month stock price forecast is 19.89, which …
What is the price of kmphus in after hours?
Apr 14, 2022 · Get KemPharm Inc (KMPH:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.
Is KMPH a good stock?
Is KEMPHARM Stock a good buy in 2022, according to Wall Street analysts? The consensus among 1 Wall Street analyst covering (NASDAQ: KMPH) stock is to Buy KMPH stock.
Why is KemPharm stock dropping?
What happened. Shares of KemPharm ( KMPH -3.35% ) were sinking 12.6% as of 3:33 p.m. EDT on Friday. The big drop came after the drugmaker announced the exercise of existing warrants and the issuance of new warrants.Jun 18, 2021
What is the long range forecast for KMPH stock?
The 2 analysts offering 12-month price forecasts for KemPharm Inc have a median target of 19.50, with a high estimate of 28.00 and a low estimate of 11.00. The median estimate represents a +355.61% increase from the last price of 4.28.
Is KemPharm a good stock?
1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for KemPharm in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" KemPharm stock.
Why did KMPH fall?
KMPH, +2.78% shares plummeted in the extended session Thursday after a Food and Drug Administration advisory committee did not recommend that abuse-deterrent labeling be added to the drug maker's painkiller. KemPharm shares dropped 60% to $6.33 after hours.May 5, 2016
How do you buy stocks on wish?
How and Where To Buy Wish Stock. If you want to buy ContextLogic Inc. stock, sign up to make an account on a trading platform and enter the requested personal information to open your brokerage account. Then you can buy the number of shares you want. The company operates under the ticker WISH.Sep 23, 2021
KemPharm Appoints Tamara A. Seymour to Board of Directors
KemPharm Reports Second Quarter 2021 Financial Results
CELEBRATION, Fla., Aug. 18, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today the appointment of Tamara A. Seymour to serve on its Board of Directors and as Chair of the Audit Committee. Ms.
KemPharm to Report Second Quarter 2021 Results
Corporate and Regulatory Highlights U.S.
Is KemPharm Inc (KMPH) A Good Stock To Buy?
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, August 12, 2021, 4:30 p.m. ET CELEBRATION, Fla., Aug. 05, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc.
Why KemPharm Stock Sank Today
In this article we will take a look at whether hedge funds think KemPharm Inc (NASDAQ:KMPH) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips from […]
KemPharm Announces Exercise of Existing Warrants and Issuance of Warrants in Private Placement
Shares of KemPharm (NASDAQ: KMPH) were sinking 12.6% as of 3:33 p.m. EDT on Friday. The big drop came after the drugmaker announced the exercise of existing warrants and the issuance of new warrants. In KemPharm's latest transaction, holders with warrants that could have been exercised for nearly 6.2 million shares received a new deal.
KemPharm Issues Letter to Shareholders
CELEBRATION, Fla., June 18, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc.
Recently Viewed Tickers
CELEBRATION, Fla., June 16, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C.
KemPharm Inc
Visit a quote page and your recently viewed tickers will be displayed here.
About KMPH
KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs.
Financial Performance
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States.
News
In 2020, KemPharm's revenue was $13.29 million, an increase of 3.50% compared to the previous year's $12.84 million. Losses were -$12.76 million, -47.97% less than in 2019.
Is KemPharm a buy right now?
CELEBRATION, Fla., Sept. 09, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced ...
What stocks does MarketBeat like better than KemPharm?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for KemPharm in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" KemPharm stock.#N#View analyst ratings for KemPharm or view top-rated stocks.
When is KemPharm's next earnings date?
Wall Street analysts have given KemPharm a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but KemPharm wasn't one of them.
How were KemPharm's earnings last quarter?
KemPharm is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.#N#View our earnings forecast for KemPharm.
How has KemPharm's stock price been impacted by COVID-19?
KemPharm, Inc. (NASDAQ:KMPH) issued its earnings results on Thursday, August, 12th. The specialty pharmaceutical company reported ($0.40) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.23 by $0.63.
What price target have analysts set for KMPH?
KemPharm's stock was trading at $0.2452 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, KMPH shares have increased by 3,684.7% and is now trading at $9.28.#N#View which stocks have been most impacted by COVID-19.
Who are some of KemPharm's key competitors?
2 brokers have issued 12 month target prices for KemPharm's shares. Their forecasts range from $12.00 to $12.00. On average, they expect KemPharm's stock price to reach $12.00 in the next year.
Signals & Forecast
Some companies that are related to KemPharm include Avid Bioservices (CDMO), Connect Biopharma (CNTB), Precigen (PGEN), Repare Therapeutics (RPTX), Heron Therapeutics (HRTX), MannKind (MNKD), GH Research (GHRS), ImmunoGen (IMGN), Olema Pharmaceuticals (OLMA), Janux Therapeutics (JANX), Enanta Pharmaceuticals (ENTA), Aclaris Therapeutics (ACRS), Innoviva (INVA), ChemoCentryx (CCXI) and Fulcrum Therapeutics (FULC).#N#View all of KMPH's competitors..
Support, Risk & Stop-loss
A buy signal was issued from a pivot bottom point on Friday, August 27, 2021, and so far it has risen 4.50%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 months Moving Average Convergence Divergence (MACD). Volume fell during the last trading day despite gaining prices.
Is KemPharm stock A Buy?
KemPharm finds support from accumulated volume at $9.10 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
